Compare Serum Klotho Levels in Patients on Oral Antidiabetic Treatment
NCT ID: NCT03585777
Last Updated: 2018-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
90 participants
OBSERVATIONAL
2018-10-11
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Urinary Uromodulin and the Corresponding Gene Expression as a Biomarker of Diabetic Nephropathy
NCT05695573
Therapeutic Drug Use for CKD Patients
NCT05818995
Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD
NCT06069076
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
NCT05887817
GLUcose Transport and REnalPROtection in Chronic Kidney Disease
NCT05998837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Design:
This study will be an observational prospective cohort study. The study duration will be 2 months.
Study Methods:
* Population of Study
* Group 1 :compare serum klotho levels in patients taking glimeperirde versus levels in patients taking metformin
* Group 2 : compare serum klotho levels in patients taking glimeperirde versus levels in patients taking linagliptin
* Group 3 : compare serum klotho levels in patients taking glimeperirde versus levels in patients taking impaglifluzin
* Inclusion Criteria :
* Group 1 :Diabetics candidate for oral treatment
* Group 2 :Diabetics candidate for oral treatment
* Group 3 :Diabetics candidate for oral treatment
* Exclusion Criteria :
Diabetics candidate for insulin treatment
There will be three arms to this study; the first arm will enroll patients on glimepiride and patients on metformin to compare serum klotho levels. The second arm will enroll patients on glimepiride and patients on linagliptin to compare serum klotho levels. The third arm will enroll patients on glimepiride and patients on impaglifluzin to compare serum klotho levels Each arm will enroll 40 patients, 20 patients on glimiperide treatment,20 patient will on the other drug,patients will be selected from Fayoum university diabetes and endocrine clinic
Data collection:
Patients will be subjected to; full clinical examination,waist hip ratio assessment,BMI assessment fasting blood glucose,2PP blood glucose,HbA1C, urea, creatinine, uric acid total calcium,albumin, phospherus, estimated GFR, ACR, total cholesterol, triglycerides, serum klotho, FGF 23 levels assessment , also fracrtional excretion of phospherus will be assessed. Control of blood glucose will be done along the period of the study. At the end of the 2 months,reassessment of the above mentioned parameters will be done.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin
No interventions assigned to this group
Group 2
Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin
No interventions assigned to this group
Group 3
Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fayoum University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Abdelkawi Hammad
Lecturer of internal medicine,faculty of medicine,Fayoum university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fayoum university Hospital
Al Fayyum, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ahmed Hammad, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VCG 3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.